Ibrutinib Plus Rituximab vs Placebo Plus Rituximab for WM: Final iNNOVATE Analysis

Key Findings

• ●At 50-month median follow-up, median PFS not reached with ibrutinib-rituximab vs 20.3 months for placebo-rituximab
• ●Sustained superiority regardless of MYD88 or CXCR4 mutation status
• ●Confirmed long-term benefit of ibrutinib-rituximab combination

Referenced in (1 disease)